News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
Automated parallel capillary electrophoresis system simplifies protein analysis
Collaboration streamlines patient access to oncology clinical trials
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Beneficiaries can create Ayushman Card from their mobile phone using Ayushman App which has been downloaded 52 lakh times since its launch on 13th September, 2023
Subscribe To Our Newsletter & Stay Updated
